Alliance Foundation Trials, Llc.

This study tests a combination of two targeted drugs, palbociclib and ibrutinib, in people with mantle cell lymphoma that has been treated before but returned. The goal is to see if the combination can control the cancer for longer. About 39 adults will take the drugs in 28-day c…

This phase 3 trial tests whether adding the drug palbociclib to standard anti-HER2 and hormone therapy can help people with a specific type of advanced breast cancer (HR+/HER2+) live longer without their disease getting worse. About 518 participants will receive either the triple…

This study tests a combination of four drugs (lenalidomide, ixazomib, dexamethasone, and daratumumab) in people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if adding two extra drugs to standard maintenance therapy can …

This study tested whether adding the drug palbociclib to standard hormone therapy for 2 years helps prevent breast cancer from coming back in people with early-stage HR+/HER2- breast cancer. About 5,800 participants were followed for at least 4 years. The goal was to see if the c…

This study tests whether adding an experimental immunotherapy drug (tiragolumab) to standard immunotherapy (atezolizumab) plus chemoradiation helps people with stage III lung cancer live longer without the disease getting worse. About 178 participants will receive either the two-…

This study compares active monitoring (regular checkups without surgery) to standard surgery for people with low-risk ductal carcinoma in situ (DCIS), a very early breast change. About 1,000 participants are being followed for two years to see if monitoring is as good as surgery …

This study looks at how two different prostate cancer medications, darolutamide and enzalutamide, affect thinking skills like memory and attention. About 111 men with advanced prostate cancer will take one of the two drugs and complete computer-based brain tests over time. The go…